<DOC>
	<DOC>NCT00585143</DOC>
	<brief_summary>Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly</brief_summary>
	<brief_title>Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion Criteria Body Mass Index (BMI) 19 to 33, inclusive Either normal kidney function, or mild or moderate kidney impairment Exclusion Criteria Use of any medications, vitamins and/or herbal supplements within 2 weeks prior to study drug administration, except those required for management of renal disease. History of epilepsy, any clinically significant cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Dyslipidemia</keyword>
</DOC>